Glivec Phase II Pediatric Study
Open Label, Pilot Phase II Study of Glivec in Children and Adolescents With Life Threatening Diseases Known to Be Associated With One or More Glivec-Sensitive Tyrosine Kinases
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Gustave Roussy, Cancer Campus, Grand Paris
- Biliary Tract Cancer · Phase PHASE2 · Feb 2025
- Breast Cancer · Phase PHASE2 · Dec 2024
- Metastatic Renal Cell Carcinoma · Phase NA · May 2024
- Ovarian Cancer · Phase PHASE1/PHASE2 · Apr 2024
- Very High Risk Neuroblastoma · Phase PHASE2 · Mar 2024
See all terminations from Gustave Roussy, Cancer Campus, Grand Paris
Listed as NCT00180830, this PHASE2 trial focuses on Cancer and remains terminated or withdrawn. Sponsored by Gustave Roussy, Cancer Campus, Grand Paris, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Dec 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gustave Roussy, Cancer Campus, Grand Paris
For direct contact, visit the study record on ClinicalTrials.gov .